4.0
1. Sept. 2025
Ehemaliger Mitarbeiter
Boston, MA
Empfehlen
CEO-Befürwortung
Geschäftsprognose
Pros
- data sciences approaches - RPM market in provider and life sciences was exploratory in 2023
Kontras
- broke up company into multiple parts and sold